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Abstract
Many insect viruses express caspase inhibitors of the P35 superfamily, which prevent defensive host apoptosis to enable
viral propagation. The prototypical P35 family member, AcP35 from Autographa californica M nucleopolyhedrovirus, has
been extensively studied. Bacterially purified AcP35 has been previously shown to inhibit caspases from insect, mammalian
and nematode species. This inhibition occurs via a pseudosubstrate mechanism involving caspase-mediated cleavage of a
‘‘reactive site loop’’ within the P35 protein, which ultimately leaves cleaved P35 covalently bound to the caspase’s active
site. We observed that AcP35 purifed from Saccharomyces cerevisae inhibited caspase activity more efficiently than AcP35
purified from Escherichia coli. This differential potency was more dramatic for another P35 family member, MaviP35, which
inhibited human caspase 3 almost 300-fold more potently when purified from yeast than bacteria. Biophysical assays
revealed that MaviP35 proteins produced in bacteria and yeast had similar primary and secondary structures. However,
bacterially produced MaviP35 possessed greater thermal stability and propensity to form higher order oligomers than its
counterpart purified from yeast. Caspase 3 could process yeast-purified MaviP35, but failed to detectably cleave bacterially
purified MaviP35. These data suggest that bacterially produced P35 proteins adopt subtly different conformations from
their yeast-expressed counterparts, which hinder caspase access to the reactive site loop to reduce the potency of caspase
inhibition, and promote aggregation. These data highlight the differential caspase inhibition by recombinant P35 proteins
purified from different sources, and caution that analyses of bacterially produced P35 family members (and perhaps other
types of proteins) may underestimate their activity.
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Introduction
Members of the caspase family of cysteine proteases are key
regulators of insect cell death [1]. Insect viruses of the baculovirus
[2] and entomopoxvirus [3] families have evolved to express
caspase inhibitors of the P35 family, which suppress the defensive
host apoptosis that their infection would otherwise trigger [4]. The
first identified and best studied P35 family member is AcP35, from
Autographa californica (Ac) M nucleopolyhedrovirus (MNPV) [5].
AcP35 possesses an extremely broad specificity, potently inhibiting
caspases from mammals and nematodes in addition to insects [6–
11]. Only a few caspases, such as Drosophila DRONC [12,13], its
putative Spodoptera ortholog Sf-caspase-x [14] and human caspase 9
[15] have been reported to withstand the inhibitory activity of
AcP35. Biochemical and structural analyses of bacterially-purified
AcP35 have defined its mechanism of action [16–19]. Caspase
cleavage of AcP35 within the so-called ‘‘reactive site loop’’ (RSL)
provokes a major conformational change that places the amino
terminus of AcP35 into the active site of the caspase, where it
prevents hydrolysis of a thioester bond between the inhibitor and
the protease [16–19]. This traps the caspase in a P35-bound form
[16] incapable of cleaving substrates. Although AcP35 inhibits a
broad range of caspases, and insect caspases are its natural targets,
AcP35 was also found to potently inhibit the bacterial cysteine
protease gingipain-K, via a similar suicide substrate mechanism to
that used by AcP35 to inhibit caspases [20].
A number of other baculoviruses encode close relatives of
AcP35. We recently reported that one of these sub-family
members, MaviP35 from Maruca vitrata MNPV [21], shared a
caspase inhibitory mechanism with AcP35 but exhibited somewhat
different specificity [22]. Some baculoviruses [23,24] encode more
distant relatives of AcP35, including members of the ‘‘P49’’ sub-
family. SpliP49 from Spodoptera littoralis NPV inhibited a broad
range of caspases, via a similar mechanism to AcP35, but unlike
AcP35 could target insect initiator caspases [7,25–28]. Amsacta
moorei entomopoxvirus encodes another distant AcP35 relative,
P33. Despite sharing only 25% amino acid identity with AcP35,
P33 inhibited apoptosis, bore a similar specificity profile to AcP35,
and mutational analyses suggested it employed a similar mecha-
nism of action [3].
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anism, potency and specificity of AcP35 and P33 have utilized C-
terminally His6-tagged bacterially-purified proteins [3,6–10,16–
20,25,29–33]. Recombinant His6-tagged SpliP49 was initially
purified from Sf-21 insect cells [25], due to insolubility in bacteria.
Subsequent inclusion of an unstructured linker between SpliP49
and the tag enabled purification of soluble SpliP49 from E. coli,
which apparently exhibited similar activity to the protein isolated
from insect cells [27].
We recently compared the activities and specificities of AcP35
and MaviP35 [22]. Here we report that, although AcP35 and
MaviP35 could be produced as abundant soluble proteins by
Saccharomyces cerevisiae and Escherichia coli, both proteins were more
potent caspase inhibitors when purified from yeast rather than
bacteria. This study explored the molecular basis for this
differential potency.
Results
Enhanced activity of AcP35 and MaviP35 following
purification from yeast
Sequencing of the MaviMNPV genome [21] revealed that this
virus encoded a P35 orthologue that was 81% identical to the
founding member of this family, AcP35, and modeling suggested
they may adopt similar structures [22]. MaviP35 was able to
inhibit both insect and mammalian cell death, confirming that it
can act as an apoptosis inhibitor [22]. To explore the caspase
inhibitory properties of AcP35 and MaviP35, we initially purified
the viral apoptosis inhibitors as C-terminally FLAG-tagged
proteins from Escherichia coli. In three separate experiments,
bacterially produced AcP35 potently inhibited the proteolytic
activity of caspase 3, but MaviP35 only partially impaired the
ability of caspase 3 to cleave a peptide substrate (data not shown).
This inefficiency was puzzling, as we had found that AcP35 and
MaviP35 conferred similar protection against yeast death triggered
by expression of active caspase 3 [22]. This discrepancy suggested
to us that the MaviP35 expressed in yeast may be a more potent
caspase inhibitor than MaviP35 expressed in bacteria. To directly
test this hypothesis, we purified FLAG-tagged MaviP35 from
Saccharomyces cerevisiae. This protein was dramatically more efficient
at inhibiting caspase 3 than its bacterially produced counterpart
(Figure 1A). Quantitation of caspase inhibition by MaviP35
purified from bacteria and yeast revealed that the protein purified
from E. coli (Figure 1B) was around 300-fold less potent than that
purified from yeast [22]. We observed a similar, but less dramatic,
difference with AcP35. Yeast-purified AcP35 inhibited caspase 3
[22] about six times more efficiently than bacterially-purified
AcP35 (Figure 1B).
Analyses of primary structures of P35 proteins purified
from bacteria and yeast
A number of possible explanations were tested to explore the
differential activities of P35 family proteins isolated from bacteria
and yeast. Mass spectrometry methods were employed to examine
the primary structures of AcP35 and MaviP35 purified from the
different sources, to determine whether post-translational modifi-
cations differed depending on the source of recombinant protein.
The proteins from both sources had molecular weights consistent
with each protein lacking its initiating methionine residue
(Figure 2A). This excluded the possibility that prokaryotic
proteases cleaved and incapacitated the bacterially-purified
inhibitors, or that large post-translational modifications which
modulated function occurred in one species but not the other.
Analysis of the amino terminal tryptic peptides generated from
each protein confirmed the absence of the initiating methionine
(Figure 2B). Similar proportions of bacterially purified AcP35 and
MaviP35 were N-acetylated (21% and 24% respectively). In
contrast, only 13% of AcP35 and only 12% of MaviP35 proteins
were N-acetylated when expressed in yeast. This difference of
around 10% between the proteins purified from bacteria and yeast
seems unlikely to account for the 280-fold superiority of yeast-
purified MaviP35 with respect to caspase inhibition (Figure 1B).
Analyses of secondary structures of MaviP35 purified
from bacteria and yeast
The above-mentioned mass spectrometry analyses suggested
that the P35 proteins expressed in bacteria and yeast had similar
primary structures. Circular dichroism (CD) spectroscopy was
used to explore the possibility that differences in secondary
structure may underlie the substantially greater activity exhibited
by yeast-purified MaviP35, relative to bacterial MaviP35. Wave-
length scans of each sample were performed to estimate the
fractions of various secondary structural elements adopted by
bacterially and yeast-expressed MaviP35 in aqueous solution. The
resulting spectra each displayed a single minimum at approxi-
mately 216 nm (Figure 3A, open circles), which is indicative of a
protein sample with predominantly b structure [34]. The CD
spectra were fitted by nonlinear least squares regression against
relevant protein databases [35,36]. The best fit for the MaviP35
samples (Figure 3A, solid line) was obtained by applying the
CONTINLL algorithm against the SP29 database. This predicted
that both samples had large proportions of b-structure (30–32%)
and unordered secondary structure (29–30%) in combination with
significant proportions of b-turn (22%) and a-helical (17–18%)
structure (Figure 3B). These secondary structure proportions
correlate well with structural predictions for MaviP35 [22] based
Figure 1. MaviP35 and AcP35 are more active when purified
from yeast than bacteria. (A) FLAG-tagged MaviP35 or AcP35 were
purified from bacteria or yeast. The indicated concentrations of
inhibitors were assayed for their ability to inhibit cleavage of 100 mM
Ac-DEVD-AFC by 30 nM caspase 3. Error bars represent S.E.M. from
three independent replicates. (B) A competitive model was used to
determine the caspase 3 inhibition constants for the P35 proteins
purified from yeast [22] and bacteria.
doi:10.1371/journal.pone.0039248.g001
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[18]. To assess thermal stability of the samples, CD thermal
denaturation studies were performed at 216 nm between 20uC
and 90uC (Figure 3C, open symbols). Nonlinear regression analysis
of the data to a one step transition model resulted in a fit with
R
2=0.9843 and 0.9737 for the bacterial and yeast samples
respectively (Figure 3C, dashed lines). These fits revealed the
apparent melting temperatures (Tmelt
app) for bacterially-produced
MaviP35 to be 72.960.1uC and yeast-isolated MaviP35 to be
69.760.3uC, suggesting that the bacterially-purified form of
MaviP35 was slightly more thermostable than the yeast-purified
form.
Comparisons of the oligomeric status of MaviP35 isolated
from bacteria and yeast
Subsequent experiments further probed the possibility that
species-dependent conformational differences may account for the
differential potencies of MaviP35 purified from yeast and bacteria.
Chemical crosslinking revealed differences in the oligomeric status
of MaviP35 proteins isolated from bacteria and yeast (Figure 4).
Crosslinking of MaviP35 isolated from yeast revealed a major
species that migrated as expected for a pentamer, and less
abundant apparent tetrameric and hexameric forms. The majority
of the bacterially-purified MaviP35 proteins migrated as mono-
mers when subjected to reducing SDS-PAGE. However, apparent
dimers and hexamers were also present despite samples being
boiled in loading dye containing b-mercaptoethanol prior to
electrophoresis. After crosslinking, the migration of the bacterially-
produced MaviP35 protein suggested the existence of oligomers
composed of four to ten monomers (Figure 4).
MaviP35 proteins isolated from E. coli and S. cerevisiae were also
subjected to gel filtration liquid chromatography (LC). The
chromatograms of proteins isolated from the two sources were
reproducibly different, throughout five separate experiments
(Figure 5A, B, data not shown). Consistent with data from
crosslinking experiments (Figure 4), none of the bacterially-
produced protein migrated as expected for a monomer. Some of
the bacterially-purified MaviP35 displayed migration consistent
with a trimer, but a substantial amount of the protein eluted much
earlier (Figure 5A), confirming the presence of the larger oligomers
and aggregates observed following crosslinking and SDS-PAGE
analysis (Figure 4). The yeast-isolated sample contained species
Figure 2. Expression in bacteria or yeast does not substantially
alter the primary structural features of MaviP35 and AcP35.
FLAG-tagged MaviP35 and AcP35 were purified from bacteria or yeast.
(A) Each sample was analyzed using Matrix Assisted Laser Desorption
Ionisation-Mass Spectrometry. (B) Reduced and alkylated proteins were
subjected to trypsin digestion, then the peptides were analyzed by LC-
ESI-MS. The intensity of peaks of masses corresponding to the predicted
peptide mass of unmodified or modified amino terminal tryptic
peptides were measured. Based on the assumption that the peak
intensities are proportional to the peptide amount, the relative amount
of each peptide was calculated. The integrities of the peptides were
confirmed by MS/MS analysis.
doi:10.1371/journal.pone.0039248.g002
Figure 3. MaviP35 proteins purified from bacteria and yeast
have similar secondary structures. FLAG-tagged MaviP35 proteins
were purified from yeast and bacteria and then subjected to circular
dichroism (CD) analyses. (A) Wavelength scans were performed at 20uC.
The final spectra is the average result of three scans (open circles). The
CONTINLL algorithm calculated the nonlinear least squares best fit
(solid line) against the SP29 protein database with r.m.s.d. val-
ues#0.073. (B) Table of secondary structure proportions and apparent
melting temperature for MaviP35 purified from bacterial and yeast. (C)
Ellipticity at 216 nm was measured between 20 and 90uC (open circles).
The nonlinear regression analysis (dashed lines) fitted the curves to a
one step transition between folded and unfolded confirmations.
doi:10.1371/journal.pone.0039248.g003
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dimers and pentamers (Figure 5B). In one experiment, fractions
corresponding to the major gel filtration peaks were further
analyzed. SDS-PAGE and anti-FLAG immunoblotting confirmed
the presence of MaviP35 in each of the major bacterial fractions
and the ,170 kDa and ,72 kDa fractions of the sample purified
from yeast (Figure 5C). Consistent with the gel filtration
chromatogram, very little monomeric MaviP35 was purified
during gel filtration LC of the yeast-purified sample. The gel
filtration LC fractions of MaviP35 purified from yeast that
contained readily detectable protein (,170 kDa and ,72 kDa)
efficiently inhibited caspase 3 activity (Figure 5D). In stark
contrast, none of the fractions containing bacterially-produced
MaviP35 affected the proteolytic activity of caspase 3 (Figure 5D),
highlighting the poor activity of prokaryotically-expressed Ma-
viP35.
To further investigate oligomeric status, gel filtration fractions of
yeast- and bacterially-produced MaviP35 corresponding to 111–
215 kDa and 89–138 kDa respectively were subjected to analytical
ultracentrifugation. Sedimentation velocity analyses suggested the
presence of predominantly tetrameric and hexameric species
within the bacterially-purified sample (with minor dimeric and
dodecameric species), whereas the majority of the yeast-isolated
sample sedimented as expected for tetramers, pentamers and
hexamers (with minor octameric species) (Fig. 6).
Differential sensitivity to caspase cleavage of MaviP35
purified from bacteria versus yeast
The pseudo-substrate mechanism of inhibition employed by
P35 proteins requires their cleavage by caspases. We reasoned that
the conformation adopted by MaviP35 expressed in bacteria may
obscure the reactive site loop and restrict its accessibility to
caspases. Gel filtration fractions from the yeast and bacterial
MaviP35 purifications were incubated with caspase 3 and their
sensitivities to cleavage were monitored by immunoblotting.
Although caspase 3 was able to cleave MaviP35 isolated from
yeast to produce the expected 25.7 kDa carboxyl terminal FLAG-
tagged product, it failed to cleave the bacterially-expressed protein
(Figure 7).
Figure 4. Bacterially produced MaviP35 is more prone to
aggregation in vitro than yeast-expressed MaviP35. FLAG-
tagged MaviP35 proteins were purified from bacteria or yeast and
then treated with 0 or 5 mM of the crosslinker BMH prior to analysis by
SDS-PAGE and anti-FLAG immunoblotting. Arrows on the right indicate
the expected positions of various oligomeric species based on the
migrations of the molecular weight markers. The expected molecular
weight of octameric MaviP35 (286 kDa) would be greater than that of
the largest marker used, so its migration is difficult to accurately
estimate. A representative immunoblot is shown from four separate
experiments.
doi:10.1371/journal.pone.0039248.g004
Figure 5. MaviP35 purified from yeast and bacteria differ in
their mobility during size exclusion chromatography. FLAG-
tagged MaviP35 proteins were purified from bacteria (A) or yeast (B)
and then subjected to gel filtration. (C) Selected fractions were analyzed
by SDS-PAGE and anti-FLAG immunoblotting. (D) Proteins from each
selected gel filtration fraction or buffer (2) were mixed with caspase 3
and then maximal rate of cleavage of Ac-DEVD-AFC was monitored
fluorometrically. (C, D) Because the yield of the yeast-purified protein
was lower than the bacterial sample, the bacterial fractions were diluted
8-fold prior to these analyses.
doi:10.1371/journal.pone.0039248.g005
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This study revealed that the caspase inhibitory capacities of
recombinant P35 proteins are influenced by the species used to
express them. Expression in yeast yielded more potent caspase
inhibitors than bacterial expression. The superiority of the yeast-
purified AcP35, relative to the bacterially-produced form, was
relatively minor. However, the difference in activities was dramatic
in the case of MaviP35. Bacteria are convenient and effective for
recombinant protein expression primarily because culturing is
easy, inexpensive, and can achieve high yields [37]. Some proteins
are not amenable to prokaryotic expression, either because the
protein of interest tends to accumulate in an insoluble form within
inclusion bodies, or because it requires eukaryotic post-transla-
tional modifications for activity [38]. In the case of these P35
family members, however, both AcP35 and MaviP35 were
abundantly expressed as soluble proteins in E. coli. We explored
the possibilities that differences in primary, secondary and
quaternary structure may account for the differential potencies
of the P35 proteins isolated from bacteria or yeast.
Because the amino terminus of AcP35 had previously been
shown to be critical for its caspase inhibitory activity, we paid
particular attention to potential species-specific post-translational
modifications affecting this region of AcP35 and MaviP35.
Unsuccessful attempts at amino-terminal sequencing of AcP35
previously led Riedl et al to speculate that the amino terminus of
bacterially-produced AcP35 was a blocked methionine residue
Figure 6. Analytical ultracentrifugation of MaviP35 purified from bacteria and yeast. (A) MaviP35-FLAG proteins were purified from
bacteria (gray line) and yeast (black line) and then subjected to gel filtration. (B–F) Analytical ultracentrifugation of the fractions indicated in gray
shading yielded the sedimentation profiles shown. The molecular weights estimated for each peak are stated. Numbers in parentheses indicate
numbers of MaviP35-FLAG monomers that could comprise the major oligomeric species resolved by analytical ultracentrifugation.
doi:10.1371/journal.pone.0039248.g006
Figure 7. Caspase 3 can cleave MaviP35 purified from yeast but
not bacteria. FLAG-tagged MaviP35 was purified from bacteria or
yeast by affinity chromotography and gel filtration. The ,94 kDa gel
filtration fraction of the bacterial preparation (‘‘b4’’ in Figure 5) and the
,72 kDa fraction of the yeast-purified sample (‘‘y3’’ in Figure 5) were
incubated with 0, 10, 100 or 1000 ng/ml caspase 3 for 1 hour, and then
subjected to SDS-PAGE and anti-FLAG immunoblotting.
doi:10.1371/journal.pone.0039248.g007
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AcP35 and MaviP35 isolated from both bacteria and yeast lacked
initiating methionine residues. This removal, presumably mediat-
ed by methionine aminopeptidases [39,40], was the only
widespread post-translational modification observed, although it
must be noted that subtle modifications which affect molecular
weight very slightly may not have been detected using the mass
spectrometry techniques we employed. Small proportions of the
amino terminal tryptic peptides from each of the proteins were N-
acetylated, but the source from which each protein was purified
influenced this only marginally. Mass spectrometry analyses of
intact proteins yielded the predicted molecular weights for full
length proteins lacking the initiating methionine residues. This
argues against the notions that bacterial proteases could cleave and
inactivate P35 proteins expressed in E. coli, or that glycosylation or
phosphorylation of the yeast-expressed P35 proteins could
enhance their activity. This study directly compared the activities
of C-terminally FLAG tagged P35 proteins isolated from bacteria
and yeast, whereas most previous biochemical analyses of AcP35
have employed purified C-terminally His6-tagged proteins. The
caspase inhibitory activities of FLAG- and His6-tagged P35
proteins were not compared, so additional research will be
required to address the possibility that different epitope tags may
differentially modulate the function of P35 proteins purified from
different sources.
Circular dichroism spectroscopy was used to explore whether
bacterial and yeast-purified MaviP35 differed in secondary
structure. We concentrated on MaviP35 for these and subsequent
analyses because its activity was more dramatically influenced than
AcP35 by the species used for expression. Bacterial and yeast
MaviP35 samples had similar secondary structure composition,
with a large proportion of b-structure and unordered structure,
and significant proportions of b-turn and a-helical structure.
There were no discernible differences between the secondary
structures of MaviP35 proteins purified from bacteria and yeast
that could account for their markedly different activities. Thermal
denaturation experiments revealed that both samples unfolded via
a single state transition with respect to secondary structure, at
72.960.1uC and 69.760.3uC for the bacterial and yeast samples
respectively. These data suggest that bacterially-produced Ma-
viP35 is slightly, but significantly, more thermostable than the
yeast purified protein, presumably because the proteins adopt
different conformations and/or oligomeric states.
Previous studies have attributed various oligomeric states to
AcP35. Dynamic light scattering suggested that bacterially-purified
AcP35 formed dimers, whereas the crystal structure of AcP35
revealed a trimeric configuration [30]. In a separate study, AcP35
(bearing hemagglutinin and His6 tags) was purified from insect
cells and observed to migrate during SDS-PAGE as expected for a
trimer when crosslinked, but a dimer without crosslinking [31].
Yeast-two hybrid and mutagenesis analyses suggested that two
molecules of AcP35 could dimerize via interactions between the
helix a1 of one protein and the b-sheet of another [31]. In this
study, we used gel filtration LC, chemical cross-linking and
analytical ultracentrifugation to explore the oligomeric status of
FLAG-tagged MaviP35 proteins purified from yeast and bacteria.
Prokaryotically-expressed MaviP35 was more prone than the
yeast-isolated protein to aggregate into higher order oligomers.
However, this tendency seemed unlikely to account for the poor
caspase inhibitory potential of this protein, because bacterially-
expressed MaviP35 samples composed predominantly of tetra-
meric and hexameric species (isolated by gel filtration) exhibited
negligible caspase inhibitory activity and were resistant to caspase
cleavage. Yeast-purified MaviP35 also formed oligomers, but data
from crosslinking and analytical ultracentrifugation studies sug-
gested the presence of pentamers in addition to tetramers and
hexamers. Gel filtration fractions containing these species
possessed strong caspase inhibitory activity and were sensitive to
caspase cleavage.
Considered together, our data show that bacterial and yeast
expression produce MaviP35 proteins with slightly different
solution properties that may reflect subtle differences in confor-
mation. We postulate that yeast expression of MaviP35 yields a
protein whose conformation permits access of a caspase to its
reactive site loop, enabling cleavage and reorientation of the
amino terminus to target the caspase’s active site. This conforma-
tion predominantly assembles into tetramers, pentamers and
hexamers. In contrast, the same protein expressed in bacteria at
the same temperature folds into a more thermostable conforma-
tion that impedes caspase access to the cleavage site within the
reactive site loop, and which forms tetramers and hexamers as well
as higher order aggregates. These distinct conformational states do
not appear to result from differential post-translational modifica-
tions, although we cannot rule out the involvement of modifica-
tions that only produce minor changes in molecular weight.
Instead, it seems likely that different conformations result from
well-described differences in folding mechanisms within bacterial
versus yeast cells [38]. We previously observed that the C-terminal
domain of thrombospondin-1 folded differently when isolated
from mammalian cells [41] compared to bacteria [42], demon-
strating that the potential for expression systems to affect protein
structure and function is not limited to P35 relatives.
Purification from yeast rather than bacteria resulted in a 280-
fold increase in inhibitory activity for MaviP35, but only a six-fold
difference for AcP35. Interestingly, SpliP49 proteins purified from
insect and bacterial cells were previously reported to be similarly
active [27]. Thus, the influence of expression systems on caspase
inhibitory activity varies between members of the P35 super-
family.
In conclusion, this study revealed that recombinant P35
proteins, especially MaviP35, exhibit stronger activity following
purification from yeast than bacteria, suggesting that the true
inhibitory potential of some P35 family members may be
underestimated from data obtained using bacterially-purified
proteins. It is possible that prokaryotic expression systems may
also affect the conformation and activity of other classes of proteins
normally expressed in eukaryotic cells.
Materials and Methods
Plasmid construction
The following plasmids have been previously described:
pGALL-(HIS3)-AcP35-FLAG [7], pGALL-(HIS3)-MaviP35-
FLAG [22], caspase 3-pET23a [22]. The 39 part of AcP35-FLAG
was excised from pGALL-(HIS3)-AcP35-FLAG with HindIII and
XbaI (blunted) and ligated into pET23a-AcP35 [43] cut with
HindIII and XhoI (blunted) to generate pET23a-AcP35-FLAG.
The MaviP35-FLAG coding region was excised from pGALL-
(HIS3)-MaviP35-FLAG with NdeI and BamHI and ligated into
pET23a to produce pET23a-MaviP35-FLAG.
Purification and testing of P35 proteins
The Saccharomyces cerevisiae yeast strain W303a was transformed
[44] and used for protein purification and immunoblotting [22] as
previously described. Yeast were grown and transgenes induced at
30uC. The BL21-(DE3)-pLysS strain of E. coli (Novagen/Merck,
Darmstadt, Germany) was transformed with the pET23a plasmids
mentioned above. Caspase 3 was purified as previously described
Yeast Expression Yields More Active P35 Proteins
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were induced with 1 mM IPTG for 6 hours at 30uC. To lyse
bacterial pellets, 5 ml BugBuster reagent (Novagen) was used per
gram of cells. After 20 min of gentle rocking at RT and
centrifugation (36,300 g; 4uC for 15 min), the supernatant was
incubated for 30–60 min at 4uC with 300 ml of Anti-FLAGH M2-
agarose slurry (Sigma-Aldrich) per liter of culture, which had been
previously washed three times with 126 resin volume washing
buffer. Phosphate-buffered saline (PBS; Amresco, Solon, Ohio,
USA) was used as a wash buffer to prepare samples for analytical
ultracentrifugation (AUC); all other gel filtration experiments used
50 mM Tris-HCl pH 7.4, 150 mM NaCl. Following incubation
with the lysates, beads were pelleted 5 min at 3,750 g at room
temperature, then washed with 326 resin volumes of washing
buffer for 10 min at 4uC rotating. Routinely, five elution fractions
were collected, each with one resin volume of wash buffer
containing 200 ng/ml FLAG peptide (Sigma-Aldrich). For each
elution step the beads were incubated for 2–5 min at 4uC with
agitation and supernatant was collected after centrifugation. After
subsequent SDS-PAGE analysis and Coomassie brilliant blue
(Sigma-Aldrich) staining, the fractions containing pure FLAG-
tagged proteins were pooled and protein concentration was
determined using the BioRad Protein Assay (BioRad) following
the manufacturer’s protocol. Quantitation of caspase inhibitory
activity was performed as previously published [22].
Crosslinking
Samples were incubated in 5 mM Bismaleimidohexane (BMH;
Thermo Scientific, Rockford, IL USA) for 30 min at room
temperature prior to boiling in loading dye containing 5% b-
mercaptoethanol and analysis by SDS-PAGE and immunoblot-
ting.
Gel filtration
Gel filtration liquid chromatography was performed using a
SuperdexS200 column (GE Healthcare, Little Chalfont, UK). The
columns were attached to an A ¨KTA purifier (GE-Healthcare) and
prepared for loading by washing the column with one matrix
volume of water (filtered and degassed via vacuum filtration
through a 0.22 mm Durapore membrane (Millipore)) and one
volume of filtered, degassed buffer (25 mM ammonium bicarbon-
ate for mass spectrometry; PBS for AUC samples; 20 mM Tris
pH 7.4, 50 mM NaCl for other experiments). Subsequently,
250 ml of the protein sample was injected onto the column via a
500 ml injection loop. Size exclusion chromatography was
performed for 1.5 column volumes at a steady flow rate of
0.6 ml/min, maximum back pressure of 1.5 MPa and fractions of
500 ml were collected. A buffer sample was collected after
completion of protein elution, to use as a control for analytical
ultracentrifugation. A protein gel filtration standard (BioRad) was
used to determine the elution profile of five proteins (thyroglob-
ulin, bovine c-globulin, chicken ovalbumin, equine myoglobin,
and vitamin B12; MW 1,350–670,000 Da).
Mass spectrometry
Matrix Assisted Laser Desorption Ionisation-Mass Spectrometry
(MALDI-MS) was performed using an Ultraflex III MALDI-tof/
tof-MS (Bruker-Daltonics, Germany). The matrix used was 2.5
dihydroxy benzoic acid. A saturated solution of the matrix was
obtained by dissolving it in water/acetonitrile of a 7:3 ratio
including 0.1% TFA. The sample was diluted in the same buffer
1:10 prior to use. Each sample was mixed with the matrix 1:1 on a
steel target plate spot and left to dry. Spectra were acquired until a
satisfactory signal to noise level was achieved.
Electrospray Ionisation-Mass Spectro-metry (ESI-MS) was
performed using a micrOTOF-Q-MS instrument (Bruker-Dal-
tonics, Germany) linked to an HPLC (Ultimate 3000, Dionex,
Holland). Each protein was diluted in 25 mM Tris pH 8.0. DTT
(10 mM, pH 8) was added and the peptides were reduced for 1 h
at 60uC, then alkylated for 20 minutes at room temperature using
a 3 times molar excess of iodoacetamide. Then 0.05 mg of trypsin
(Promega) was added and the proteins were digested for 2 h at
40uC. The resulting peptides were injected onto a trapping column
(Dionex Acclaim Pepmap100 nanotrap 100 mm62 cm, C18,
5 mm, 100 A ˚) using A-buffer (2% acetonitrile in 0.1% formic acid
(aq); Sigma-Aldrich). Following a 6 minutes wash the sample was
transferred onto a resolving column (Dionex Acclaim Pepmap
RSLC, 75 mm615 cm, C18, 5 mm, 100 A ˚) and eluted with a
gradient of B-buffer (98% acetonitrile in A-buffer) over 70 min-
utes. The eluent from the column was directly electrosprayed into
the mass spectrometer. Mass data was continuously acquired and
for each MS spectrum three MS/MS were recorded of the most
intense peaks. The data was annotated and deconvoluted using the
Data Analysis program (Bruker-Daltonics) and the intensity of the
peaks corresponding to all variants of the N-terminal peptide were
manually recorded. The sequence of the peptides were confirmed
by MS/MS analysis using Biotools and Sequence Editor (Bruker-
Daltonics) as well as by manual inspection and peak assignment.
Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were recorded using an AVIV
Model 410-SF CD spectrometer. Wavelength scans were per-
formed between 190 and 260 nm in 20 mM Tris, 50 mM NaCl
pH 7.4 with a sample concentration of 105 mg/ml in 1 mm quartz
cuvettes at 20uC. Data collected below 194 nm were removed
from analysis due to poor signal-to-noise. To monitor thermosta-
bility, thermal denaturation experiments were performed at 0.5uC
increments between 20 and 90uC. Data were analyzed using the
CDPro software package [35].
Analytical ultracentrifugation
Sedimentation velocity experiments were conducted in a
Beckman model XL-I analytical ultracentrifuge at a temperature
of 20uC. All samples were solubilized in PBS. The samples were
loaded into a conventional double sector quartz cell and mounted
in a Beckman 4-hole An-60 Ti rotor at an initial concentration of
0.28 mM and 0.56 mM for the two bacterial fractions analyzed
(denoted 1 and 2 in Figure 6) respectively and 1.95 mM, 2.23 mM
and 1.39 mM for the yeast fractions (labeled 1, 2 and 3 in Figure 6),
respectively. 380 ml of sample and 400 ml of reference solution
were centrifuged at a rotor speed of 40,000 rpm, and the data
were collected at a single wavelength (230 nm) in continuous
mode, using a step-size of 0.003 cm without averaging. An
estimate of the partial specific volume (0.7358 ml/g) was
computed using the program SEDNTERP [45]. Sedimentation
velocity data at multiple time points were fitted to a continuous
sedimentation coefficient [c(s)] distribution and a continuous mass
[c(M)] distribution model [46–48] using the program SEDFIT,
which is available at www.analyticalultracentrifugation.com.
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